Monday, October 26, 2026

Private Credit Funds Hit Brakes on Withdrawals as Asset Sales Signal Portfolio Stress

Blue Owl halted quarterly withdrawals from its retail fund while New Mountain Finance sold assets at a discount, sending shares to 2020 lows. FS KKR Capital cut dividends as BDC managers defend valuations amid questions about mark-to-model pricing versus secondary market reality.

Private Credit Funds Hit Brakes on Withdrawals as Asset Sales Signal Portfolio Stress
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Blue Owl Capital suspended quarterly withdrawals from its retail private credit fund, marking the latest liquidity restriction in a sector facing questions about hidden losses. The move follows FS KKR Capital's dividend cut and New Mountain Finance's distressed asset sale that pushed shares to their lowest level since 2020.

New Mountain sold assets at a discount to book value, a transaction that exposed the gap between reported net asset values and actual market prices. Secondary market pricing for private credit positions is running below the mark-to-model valuations many funds use for quarterly reporting.

Bank of America rated Blue Owl a buy "amid misinformation," defensive language that suggests analysts are fielding client concerns about portfolio quality. The firm's withdrawal halt prevents investors from testing fund valuations with redemption requests.

Gladstone Capital management said they "feel better about non-accrual names than a year ago" despite challenging M&A valuations, an optimistic stance that contrasts with market signals. Non-accrual rates measure loans no longer generating interest income, a key credit quality metric for business development companies.

The convergence of withdrawal restrictions, dividend cuts, and below-NAV asset sales suggests private credit portfolios face deterioration masked by quarterly valuation methods. Funds typically mark holdings to internal models rather than observable market prices, creating potential gaps when forced to transact.

European insurers are distancing themselves from private credit exposure. AXA CEO Thomas Buberl noted the firm's exposure sits "far below that of rivals," while Allianz's Claire-Marie Coste-Lepoutre said she remains "very comfortable" with current positions. The comments suggest institutional investors see reason for caution.

Withdrawal restrictions and asset sales at distressed prices provide the clearest test of private credit valuations. When funds must transact rather than mark to model, the difference between reported NAVs and actual prices becomes visible. The timing of Blue Owl's withdrawal halt before quarter-end could delay potential write-downs that secondary market activity might otherwise force.

Investors watching for credit stress signals should track covenant violation disclosures in BDC quarterly filings, changes in independent valuation firms, and correlation between withdrawal timing and subsequent portfolio adjustments.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com